GORMAN KEVIN CHARLES
SEC CIK 1201096 · EDGAR
BoughtSold
Most active insiders at NBIX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | GORMAN KEVIN CHARLES | Dir | — | $37.82M |
| 2 | Cooke Julie | CHRO | — | $5.77M |
| 3 | Gano Kyle | CEO, Dir | — | $4.87M |
| 4 | Lippoldt Darin | CLO | — | $4.20M |
| 5 | SHERWIN STEPHEN A | Dir | — | $4.13M |
| 6 | Delaet Ingrid | Chief Regulatory Off | — | $3.75M |
| 7 | Onyia Jude | CSO | — | $3.47M |
| 8 | RASTETTER WILLIAM H | Dir | — | $2.73M |
| 9 | POPS RICHARD F | Dir | — | $2.36M |
| 10 | LYONS GARY A | Dir | — | $2.29M |
Transactions 38
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-15 17:05 | 2026-09-11 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | A - Grant | $0.00 | +14.3K | 525.6K | +3% | $0 | |
| 2026-09-15 17:05 | 2026-09-11 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | F - Tax | $156.22 | -7,839 | 517.8K | -1% | -$1.22M | |
| D | 2026-07-08 18:54 | 2026-06-16 | XNCR | Xencor Inc | GORMAN KEVIN CHARLES | Dir | A - Grant | $0.00 | +10.3K | 21.7K | +91% | $0 |
| T | 2026-06-17 16:02 | 2026-06-15 | XNCR | Xencor Inc | GORMAN KEVIN CHARLES | Dir | S - Sale | $12.31 | -7,527 | 11.4K | -40% | -$92.7K |
| DT | 2026-05-21 17:49 | 2026-05-19 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | M - OptEx | $43.24 | +205.1K | 756.4K | +37% | +$8.87M |
| DT | 2026-05-21 17:49 | 2026-05-19 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | S - Sale+OE | $154.33 | -245.1K | 511.3K | -32% | -$37.82M |
| DM | 2026-02-17 | 2026-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | F - Tax | $124.12 | -40.3K | 519.5K | -7% | -$5.00M |
| D | 2026-02-17 | 2026-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | A - Grant | $0.00 | +63.7K | 585.7K | +12% | $0 |
| DM | 2026-02-17 | 2026-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | M - OptEx | $0.00 | +11.0K | 524.9K | +2% | $0 |
| D | 2026-02-03 | 2026-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | F - Tax | $136.06 | -2,845 | 516.9K | -0.5% | -$387.1K |
| D | 2026-02-03 | 2026-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | M - OptEx | $0.00 | +5,142 | 519.7K | +1.0% | $0 |
| D | 2025-08-11 | 2025-08-07 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | M - OptEx | $35.99 | +106.3K | 620.9K | +21% | +$3.83M |
| D | 2025-08-11 | 2025-08-07 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | S - Sale+OE | $126.41 | -106.3K | 514.6K | -17% | -$13.44M |
| D | 2025-06-16 | 2025-06-12 | XNCR | Xencor Inc | GORMAN KEVIN CHARLES | Dir | A - Grant | $0.00 | +13.7K | 22.1K | +163% | $0 |
| D | 2025-06-16 | 2025-06-16 | XNCR | Xencor Inc | GORMAN KEVIN CHARLES | Dir | S - Sale | $9.22 | -3,173 | 18.9K | -14% | -$29.3K |
| 2025-05-29 | 2025-05-27 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | S - Sale | $120.38 | -9,613 | 514.6K | -2% | -$1.16M | |
| DM | 2025-02-14 | 2025-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | S - Sale+OE | $116.68 | -5,844 | 524.2K | -1% | -$681.9K |
| DM | 2025-02-14 | 2025-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | M - OptEx | $0.00 | +11.0K | 527.2K | +2% | $0 |
| D | 2025-02-12 | 2025-02-10 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | S - Sale+OE | $118.37 | -2,274 | 519.1K | -0.4% | -$269.2K |
| D | 2025-02-12 | 2025-02-08 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | M - OptEx | $0.00 | +4,318 | 521.3K | +0.8% | $0 |
| D | 2025-02-04 | 2025-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | S - Sale+OE | $152.92 | -2,707 | 517.0K | -0.5% | -$414.0K |
| D | 2025-02-04 | 2025-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | M - OptEx | $0.00 | +5,141 | 519.7K | +1.0% | $0 |
| D | 2025-01-29 | 2025-01-27 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | S - Sale+OE | $149.46 | -146.1K | 514.6K | -22% | -$21.84M |
| D | 2025-01-29 | 2025-01-27 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Dir | M - OptEx | $32.99 | +146.1K | 660.7K | +28% | +$4.82M |
| 2024-10-01 | 2024-09-27 | XNCR | Xencor Inc | GORMAN KEVIN CHARLES | Dir | S - Sale | $20.68 | -2,654 | 8,392 | -24% | -$54.9K | |
| D | 2024-06-17 | 2024-06-13 | XNCR | Xencor Inc | GORMAN KEVIN CHARLES | Dir | A - Grant | $0.00 | +5,986 | 11.0K | +118% | $0 |
| D | 2024-02-15 | 2024-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | CEO, Dir | S - Sale | $133.02 | -2,832 | 514.6K | -0.5% | -$376.7K |
| 2024-02-15 | 2024-02-13 | XNCR | Xencor Inc | GORMAN KEVIN CHARLES | Dir | P - Purchase | $19.12 | +53 | 5,060 | +1% | +$1,013 | |
| DM | 2024-02-14 | 2024-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | CEO, Dir | M - OptEx | $39.28 | +5,090 | 512.1K | +1% | +$200.0K |
| M | 2024-02-08 | 2024-02-06+ | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | CEO, Dir | S - Sale | $138.74 | -5,314 | 507.0K | -1% | -$737.3K |
| 2024-02-02 | 2024-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | CEO, Dir | S - Sale | $140.69 | -2,707 | 502.2K | -0.5% | -$380.8K | |
| DM | 2024-01-10 | 2024-01-08+ | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | CEO, Dir | M - OptEx | $19.59 | +167.9K | 561.8K | +43% | +$3.29M |
| DM | 2024-01-10 | 2024-01-08+ | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | CEO, Dir | S - Sale+OE | $133.02 | -167.9K | 499.8K | -25% | -$22.33M |
| 2023-08-23 | 2023-08-21 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | CEO, Dir | S - Sale | $107.40 | -9,328 | 499.8K | -2% | -$1.00M | |
| D | 2023-06-22 | 2023-06-20 | XNCR | Xencor Inc | GORMAN KEVIN CHARLES | Dir | A - Grant | $0.00 | +5,007 | 5,007 | New | $0 |
| M | 2023-02-08 | 2023-02-06+ | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | CEO, Dir | S - Sale | $102.90 | -29.0K | 470.9K | -6% | -$2.99M |
| 2023-02-02 | 2023-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | CEO, Dir | S - Sale | $110.08 | -2,707 | 465.3K | -0.6% | -$298.0K | |
| M | 2022-02-09 | 2022-02-07+ | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | CEO, Dir | S - Sale | $80.54 | -11.0K | 462.8K | -2% | -$884.7K |
Purchase Sale Sale after option exercise All abbreviations